

# Agneta Nordberg

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1122772/agneta-nordberg-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

365  
papers

26,307  
citations

79  
h-index

152  
g-index

383  
ext. papers

29,793  
ext. citations

5.8  
avg, IF

6.9  
L-index

#	Paper	IF	Citations
365	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , <b>2004</b> , 55, 306-19	9.4	3088
364	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 614-29	24.1	1985
363	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 455-532	24.1	921
362	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
361	Neuronal nicotinic receptors in the human brain. <i>Progress in Neurobiology</i> , <b>2000</b> , 61, 75-111	10.9	641
360	PET imaging of amyloid deposition in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 1456-65	5.6	533
359	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , <b>2006</b> , 129, 2856-66	11.2	513
358	Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , <b>1986</b> , 72, 115-9	3.3	386
357	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1939-49	27.4	379
356	Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1998</b> , 9, 246-57	2.6	363
355	PET imaging of amyloid in Alzheimer's disease. <i>Lancet Neurology, The</i> , <b>2004</b> , 3, 519-27	24.1	358
354	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 661-676	24.1	308
353	Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 37-46	8.9	287
352	Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). <i>Neurobiology of Aging</i> , <b>1983</b> , 4, 261-71	5.6	287
351	The use of PET in Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 78-87	15	274
350	Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. <i>Biological Psychiatry</i> , <b>2001</b> , 49, 200-10	7.9	273
349	Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. <i>NeuroReport</i> , <b>1999</b> , 10, 1779-82	1.7	252

348	Tau PET imaging in neurodegenerative tauopathies-still a challenge. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1112-1134	4.1	251
347	Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. <i>Drug Safety</i> , <b>1998</b> , 19, 465-80	5.1	250
346	Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. <i>Clinical Neurophysiology</i> , <b>2000</b> , 111, 1817-24	4.3	241
345	Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. <i>Journal of Neurochemistry</i> , <b>2000</b> , 74, 237-43	6	214
344	Brain activation in young and older adults during implicit and explicit retrieval. <i>Journal of Cognitive Neuroscience</i> , <b>1997</b> , 9, 378-91	3.1	186
343	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2016</b> , 139, 922-36	11.2	177
342	Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. <i>Alzheimer Disease and Associated Disorders</i> , <b>1995</b> , 9, 21-7	2.5	177
341	A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. <i>primary care companion for CNS disorders, The</i> , <b>2013</b> , 15,	1.2	174
340	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , <b>2013</b> , 81, 487-500	6.5	173
339	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 19	19	172
338	Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. <i>Molecular Brain Research</i> , <b>1999</b> , 66, 94-103		167
337	A critical discussion of the role of neuroimaging in mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , <b>2003</b> , 179, 52-76	3.8	153
336	Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. <i>Journal of Chemical Neuroanatomy</i> , <b>2001</b> , 22, 115-26	3.2	153
335	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 104-14	8.8	148
334	Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). <i>Journal of Neurochemistry</i> , <b>2002</b> , 81, 655-8	6	142
333	In vivo amyloid imaging with PET in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 100-6	8.8	137
332	Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. <i>Journal of Neuroimmunology</i> , <b>2002</b> , 126, 50-7	3.5	136
331	Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. <i>NeuroReport</i> , <b>1995</b> , 6, 2419-23	1.7	135

330	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. <i>Neurobiology of Aging</i> , <b>1992</b> , 13, 747-58	5.6	135
329	Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. <i>Developmental Brain Research</i> , <b>1998</b> , 108, 147-60		133
328	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , <b>2013</b> , 80, 1048-56	6.5	131
327	Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. <i>Behavioural Brain Research</i> , <b>1993</b> , 57, 255-61	3.4	130
326	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , <b>2017</b> , 140, 764-780	11.2	125
325	Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. <i>Neurochemistry International</i> , <b>2003</b> , 43, 243-9	4.4	123
324	Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. <i>Glia</i> , <b>2007</b> , 55, 385-99	9	122
323	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. <i>Trends in Pharmacological Sciences</i> , <b>2005</b> , 26, 104-11	13.2	114
322	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. <i>Neurology</i> , <b>2012</b> , 79, 229-36	6.5	112
321	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , <b>2008</b> , 63, 621-31	9.4	111
320	Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. <i>European Journal of Neuroscience</i> , <b>2004</b> , 19, 2703-10	3.5	110
319	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <i>Brain</i> , <b>2011</b> , 134, 301-17	11.2	109
318	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. <i>Psychopharmacology</i> , <b>2006</b> , 188, 509-20	4.7	109
317	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , <b>2019</b> , 25, 77-95	11.5	108
316	Postnatal changes of nicotinic acetylcholine receptor alpha 2, alpha 3, alpha 4, alpha 7 and beta 2 subunits genes expression in rat brain. <i>International Journal of Developmental Neuroscience</i> , <b>1998</b> , 16, 507-18	2.7	107
315	High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. <i>Experimental Neurology</i> , <b>2005</b> , 192, 215-25	5.7	105
314	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 198.e1-14	5.6	103
313	Cholinergic receptors in human hippocampus-- regional distribution and variance with age. <i>Life Sciences</i> , <b>1981</b> , 29, 1937-44	6.8	103

312	Human nicotinic receptors--their role in aging and dementia. <i>Neurochemistry International</i> , <b>1994</b> , 25, 93-102	7.4	102
311	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 579-93	10.9	100
310	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1686-99	8.8	98
309	Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. <i>Biochemical and Biophysical Research Communications</i> , <b>1989</b> , 165, 766-71	3.4	97
308	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , <b>2020</b> , 19, 951-962	24.1	95
307	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1316-22	8.9	94
306	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. <i>Brain</i> , <b>2013</b> , 136, 2217-27	27.2	94
305	Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. <i>Journal of Neural Transmission</i> , <b>1986</b> , 67, 275-85	4.3	94
304	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
303	Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2012</b> , 33, 18-28	2.6	93
302	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta$ in a multicentre European memory clinic study. <i>Brain</i> , <b>2016</b> , 139, 2540-53	11.2	93
301	Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, S12-8	2.5	92
300	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 274-284	1.2	91
299	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 285-295	1.2	88
298	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , <b>2021</b> , 20, 484-496	24.1	86
297	Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. <i>Brain Research</i> , <b>1998</b> , 801, 143-9	3.7	85
296	Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1997</b> , 8, 78-84	2.6	83
295	Smoking during pregnancy: a way to transfer the addiction to the next generation?. <i>Respiration</i> , <b>2002</b> , 69, 289-93	3.7	83

294	Regional deposition of inhaled <sup>11</sup> C-nicotine vapor in the human airway as visualized by positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 57, 309-17	6.1	82
293	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 30	9	82
292	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1119-32	8.8	81
291	Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , <b>1988</b> , 86, 317-21	3.3	81
290	Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. <i>NeuroReport</i> , <b>1998</b> , 9, 1519-22	1.7	80
289	Muscarinic receptor compensation in hippocampus of Alzheimer patients. <i>Journal of Neural Transmission</i> , <b>1983</b> , 56, 13-9	4.3	80
288	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , <b>2015</b> , 5, 16404	4.9	79
287	Development of ligands for in vivo imaging of cerebral nicotinic receptors. <i>Behavioural Brain Research</i> , <b>2000</b> , 113, 143-57	3.4	79
286	Biological subtypes of Alzheimer disease: A systematic review and meta-analysis. <i>Neurology</i> , <b>2020</b> , 94, 436-448	6.5	77
285	Different amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 825.e1-13	5.6	76
284	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. <i>Behavior Genetics</i> , <b>1995</b> , 25, 149-59	3.2	76
283	Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. <i>Journal of Lipid Research</i> , <b>2011</b> , 52, 1004-10	6.3	73
282	[[ <sup>11</sup> C]PIB-amyloid binding and levels of Aβ <sub>40</sub> and Aβ <sub>42</sub> in postmortem brain tissue from Alzheimer patients. <i>Neurochemistry International</i> , <b>2009</b> , 54, 347-57	4.4	72
281	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12506-11	11.5	72
280	Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. <i>Developmental Brain Research</i> , <b>1991</b> , 63, 201-7		72
279	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. <i>Molecular Psychiatry</i> , <b>2018</b> , 23, 1666-1673	15.1	69
278	Amyloid imaging in Alzheimer's disease. <i>Current Opinion in Neurology</i> , <b>2007</b> , 20, 398-402	7.1	69
277	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 183-195	5.6	67

276	Comparative analysis of nicotine-like receptor-ligand interactions in rodent brain homogenate. <i>Journal of Neurochemistry</i> , <b>1985</b> , 45, 24-31	6	67
275	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 96	9	65
274	Effects of two pyrethroids, bioallethrin and deltamethrin, on subpopulations of muscarinic and nicotinic receptors in the neonatal mouse brain. <i>Toxicology and Applied Pharmacology</i> , <b>1990</b> , 102, 456-63 <sup>4.6</sup>	4.6	65
273	Glial Asthenia and Functional Paralysis: A New Perspective on Neurodegeneration and Alzheimer's Disease. <i>Neuroscientist</i> , <b>2015</b> , 21, 552-568	7.6	64
272	Coupling of muscarinic receptors to GTP proteins in postmortem human brain--alterations in Alzheimer's disease. <i>Neuroscience Letters</i> , <b>1993</b> , 150, 39-43	3.3	64
271	Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. <i>Brain Research</i> , <b>1992</b> , 596, 142-8	3.7	64
270	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 232-236	5.2	60
269	Amyloid plaque imaging in vivo: current achievement and future prospects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35 Suppl 1, S46-50	8.8	60
268	Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42). <i>Neurochemistry International</i> , <b>2005</b> , 47, 281-90	4.4	60
267	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , <b>2003</b> , 13, 781-9, ix	3	60
266	Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. <i>Brain Research</i> , <b>1990</b> , 521, 329-32	3.7	60
265	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1191-201	1.2	59
264	Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. <i>Journal of Neurochemistry</i> , <b>2000</b> , 74, 777-84	6	59
263	Clinical studies in Alzheimer patients with positron emission tomography. <i>Behavioural Brain Research</i> , <b>1993</b> , 57, 215-24	3.4	59
262	Amyloid imaging in Alzheimer's disease. <i>Neuropsychologia</i> , <b>2008</b> , 46, 1636-41	3.2	58
261	Selective nicotinic receptor consequences in APP(SWE) transgenic mice. <i>Molecular and Cellular Neurosciences</i> , <b>2002</b> , 20, 354-65	4.8	58
260	Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. <i>Alzheimer Disease and Associated Disorders</i> , <b>1998</b> , 12, 228-37	2.5	58
259	Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. <i>Current Alzheimer Research</i> , <b>2009</b> , 6, 4-14	3	57

258	The effect of nicotine and cytisine on 3H-acetylcholine release from cortical slices of guinea-pig brain. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1985</b> , 331, 293-6	3.4	57
257	Modulation of $\alpha 7$ nicotinic acetylcholine receptor and fibrillar amyloid- $\beta$ interactions in Alzheimer's disease brain. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 841-51	4.3	56
256	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 438-46	8.8	54
255	Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 168-84	5.6	54
254	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 214-227	5.6	52
253	Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1998</b> , 357, 176-82	3.4	52
252	Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. <i>Journal of Neurochemistry</i> , <b>1999</b> , 72, 1161-9	6	51
251	Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APP <sup>sw</sup> ) transgenic mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 317, 30-6	4.7	51
250	Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. <i>Acta Neuropathologica Communications</i> , <b>2015</b> , 3, 40	7.3	50
249	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. <i>Brain Research</i> , <b>2002</b> , 956, 358-66	3.7	50
248	Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 593-4	6.1	49
247	Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. <i>Neuroscience Letters</i> , <b>1989</b> , 101, 247-52	3.3	49
246	Effect of long-term nicotine treatment on [3H]nicotine binding sites in the rats brain. <i>Drug and Alcohol Dependence</i> , <b>1985</b> , 16, 9-17	4.9	49
245	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , <b>2016</b> , 86, 50-8	6.5	48
244	Chronic fluoride toxicity decreases the number of nicotinic acetylcholine receptors in rat brain. <i>Neurotoxicology and Teratology</i> , <b>2002</b> , 24, 751-7	3.9	48
243	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 960-966	8.9	47
242	Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1071-7	8.9	47
241	Target-specific PET probes for neurodegenerative disorders related to dementia. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1418-30	8.9	47



240	Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. <i>Psychopharmacology</i> , <b>2007</b> , 191, 1005-14	4.7	47
239	Astrocytosis measured by $^{11}\text{C}$ -deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 2120-6	8.8	46
238	Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e54887	3.7	46
237	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1369-1382	8.8	45
236	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 195-206.e1	1.2	45
235	Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity--a mechanism relating to a damage at the level in post-transcription of the receptor genes. <i>Toxicology</i> , <b>2004</b> , 200, 169-77	4.4	45
234	Biological markers and the cholinergic hypothesis in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , <b>1992</b> , 139, 54-8	3.8	45
233	Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 929-39	4.3	44
232	Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , <b>1998</b> , 254, 85-8	3.3	44
231	Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. <i>Neurobiology of Disease</i> , <b>2006</b> , 24, 326-33	7.5	44
230	Unidirectional Influx and Net Accumulation of PIB. <i>Open Neuroimaging Journal</i> , <b>2008</b> , 2, 114-25	0.1	44
229	Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 1757-1767	5.7	43
228	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 289-98	1.9	43
227	The apolipoprotein E $\epsilon$ 4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1236-48	5.6	42
226	The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. <i>Neurochemistry International</i> , <b>2007</b> , 51, 377-83	4.4	42
225	Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. <i>Journal of Neurochemistry</i> , <b>1998</b> , 70, 2028-37	6	42
224	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1316-28	1.2	41
223	Tracer Kinetic Analysis of (S)- $^{11}\text{C}$ -THK5117 as a PET Tracer for Assessing Tau Pathology. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 574-81	8.9	41

222	Dementia in 2014. Towards early diagnosis in Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 69-70	15	41
221	The use of PIB-PET as a dual pathological and functional biomarker in AD. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2012</b> , 1822, 380-5	6.9	41
220	Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 2320.e15-32	5.6	41
219	Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. <i>Journal of Neuroimmunology</i> , <b>1996</b> , 68, 139-44	3.5	41
218	Effects of chronic treatment with (+)- and (-)-nicotine on nicotinic acetylcholine receptors and N-methyl-D-aspartate receptors in rat brain. <i>Brain Research</i> , <b>1994</b> , 644, 32-9	3.7	41
217	Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid- $\beta$ (1-42) Fibril by Molecular Docking and Molecular Dynamics Methods. <i>Journal of Physical Chemistry B</i> , <b>2015</b> , 119, 11560-74	7.4	40
216	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1388-99	5.6	40
215	Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons. <i>Journal of Cellular and Molecular Medicine</i> , <b>2010</b> , 14, 1476-84	5.6	40
214	The alpha7 nicotinic receptors in human fetal brain and spinal cord. <i>Journal of Neurochemistry</i> , <b>2002</b> , 80, 457-65	6	40
213	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. <i>Journal of Neurology</i> , <b>1994</b> , 242, S12-5	5.5	40
212	Chronic nicotine exposure in rat: a behavioural and biochemical study of tolerance. <i>Drug and Alcohol Dependence</i> , <b>1981</b> , 8, 51-60	4.9	40
211	Functional interactions of fibrillar and oligomeric amyloid- $\beta$ with alpha7 nicotinic receptors in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 23, 335-47	4.3	39
210	Cholinergic activity in hippocampus in chronic alcoholism. <i>Drug and Alcohol Dependence</i> , <b>1982</b> , 10, 333-44	4.9	39
209	$^3$ H-deprenyl and $^3$ H-PIB autoradiography show different laminar distributions of astroglia and fibrillar $\beta$ amyloid in Alzheimer brain. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 90	10.1	38
208	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 2465-81	5.6	38
207	Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic $\alpha$ 7 Nicotinic Receptor Drugs. <i>Neural Plasticity</i> , <b>2015</b> , 2015, 370432	3.3	38
206	Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 109-23	4.3	38
205	Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 635-46	1.9	38

204	The competition of (-)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1993</b> , 348, 28-34	3.4	38
203	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
202	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. <i>Alzheimer's Research and Therapy</i> , <b>2011</b> , 3, 34	9	36
201	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. <i>Neuroscience Letters</i> , <b>1997</b> , 232, 37-40	3.3	36
200	Influence of development and aging on nicotinic receptor subtypes in rodent brain. <i>International Journal of Developmental Neuroscience</i> , <b>1990</b> , 8, 715-21	2.7	36
199	Comparability of [F]THK5317 and [C]PIB blood flow proxy images with [F]FDG positron emission tomography in Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2017</b> , 37, 740-749	7.3	35
198	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 59, 603-614	4.3	35
197	$\beta$ Amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. <i>PLoS ONE</i> , <b>2010</b> , 5, e15600	3.7	35
196	Regional [(3)H]acetylcholine and [(3)H]nicotine binding in developing mouse brain. <i>International Journal of Developmental Neuroscience</i> , <b>1985</b> , 3, 667-71	2.7	35
195	Regional tau deposition measured by [F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 38	9	35
194	Effect of nicotine on passive avoidance behaviour and motoric activity in mice. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1985</b> , 56, 337-41		34
193	Tacrine interacts with an allosteric activator site on alpha 4 beta 2 nAChRs in M10 cells. <i>NeuroReport</i> , <b>1996</b> , 7, 2201-5	1.7	34
192	Distribution of nicotinic receptors in human thalamus as visualized by 3H-nicotine and 3H-acetylcholine receptor autoradiography. <i>Journal of Neural Transmission</i> , <b>1988</b> , 73, 77-83	4.3	34
191	Effect of sodium pentobarbital on the apparent turnover of acetylcholine in different brain regions. <i>Acta Physiologica Scandinavica</i> , <b>1977</b> , 99, 336-44		33
190	Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 1077-88	4.3	32
189	Regulation of alpha 4 beta 2 nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. <i>NeuroReport</i> , <b>1995</b> , 6, 313-7	1.7	32
188	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 18-29	5.6	31
187	Higher expression of alpha7 nicotinic acetylcholine receptors in human fetal compared to adult brain. <i>Developmental Brain Research</i> , <b>2003</b> , 142, 151-60		31

186	Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. <i>Journal of Neuroscience Research</i> , <b>2001</b> , 66, 551-8	4.4	30
185	Expression of nicotinic acetylcholine receptors in human and rat adrenal medulla. <i>Life Sciences</i> , <b>2001</b> , 70, 577-90	6.8	30
184	Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid- $\beta$ levels. <i>PLoS ONE</i> , <b>2013</b> , 8, e58752	3.7	30
183	Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by H-THK5117 and H-deprenyl autoradiography. <i>Scientific Reports</i> , <b>2017</b> , 7, 45496	4.9	29
182	Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. <i>Neuroscience Letters</i> , <b>1986</b> , 70, 160-4	3.3	29
181	Subchronic treatment of rats with nicotine: effects on tolerance and on [3H]acetylcholine and [3H]nicotine binding in the brain. <i>Drug and Alcohol Dependence</i> , <b>1986</b> , 17, 37-45	4.9	29
180	The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. <i>Journal of Physical Chemistry Letters</i> , <b>2016</b> , 7, 3313-21	6.4	29
179	Imaging $\beta$ amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 362-373	8.8	28
178	Effect of huprine X on $\beta$ amyloid, synaptophysin and $\alpha$ neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice. <i>Neurodegenerative Diseases</i> , <b>2010</b> , 7, 379-88	2.3	28
177	In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. <i>Nuclear Medicine and Biology</i> , <b>1999</b> , 26, 633-40	2.1	28
176	Muscarinic binding sites in small homogenates and in autoradiographic sections from rat and human spinal cord. <i>Brain Research</i> , <b>1984</b> , 300, 327-33	3.7	28
175	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , <b>2017</b> , 1670, 220-234	3.7	27
174	Apolipoprotein $\beta$ modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 443-58	4.3	27
173	Chronic ethanol treatment decreases [3H]epibatidine and [3H]nicotine binding and differentially regulates mRNA levels of nicotinic acetylcholine receptor subunits expressed in M10 and SH-SY5Y neuroblastoma cells. <i>Journal of Neurochemistry</i> , <b>1998</b> , 70, 1134-42	6	27
172	A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1999</b> , 10, 526-33	2.6	27
171	Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1605-1617	8.8	27
170	Clinical impact of [F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1276-1286	8.8	26
169	Increased number of muscarinic binding sites in brain following chronic barbiturate treatment to rat. <i>Life Sciences</i> , <b>1980</b> , 26, 231-7	6.8	26

168	Amyloid imaging in early detection of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , <b>2010</b> , 7, 136-8	2.3	25
167	Transgenic mice as a model for Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2011</b> , 8, 818-31	3	25
166	Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. <i>Neurochemistry International</i> , <b>2006</b> , 49, 459-65	4.4	25
165	Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. <i>Journal of Molecular Neuroscience</i> , <b>2002</b> , 18, 211-22	3.3	25
164	Early diagnosis of Alzheimer disease with positron emission tomography. <i>Alzheimer Disease and Associated Disorders</i> , <b>2000</b> , 14 Suppl 1, S109-13	2.5	25
163	Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. <i>Brain Research</i> , <b>1996</b> , 726, 207-212	3.7	25
162	In vivo detection of neurotransmitter changes in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , <b>1993</b> , 695, 27-33	6.5	25
161	Biosynthesis of acetylcholine in different brain regions in vivo following alternative methods of sacrifice by microwave irradiation. <i>Acta Physiologica Scandinavica</i> , <b>1976</b> , 98, 307-17		25
160	Amyloid- $\beta$ peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAACs. <i>Brain</i> , <b>2016</b> , 139, 174-92	11.2	24
159	Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 495-506	4.3	24
158	Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. <i>Brain Research</i> , <b>1993</b> , 620, 42-8	3.7	24
157	Changes in populations of cholinergic binding sites in brain after chronic exposure to barbital in rats. <i>Brain Research</i> , <b>1982</b> , 246, 105-12	3.7	24
156	The relevance of cerebrospinal fluid $\beta$ synuclein levels to sporadic and familial Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , <b>2018</b> , 6, 130	7.3	24
155	Spatial Normalization of F-Flutemetamol PET Images Using an Adaptive Principal-Component Template. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 285-291	8.9	23
154	(S)-(-)-[11C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. <i>Alzheimer Disease and Associated Disorders</i> , <b>1998</b> , 12, 238-46	2.5	23
153	[3H]acetylcholine nicotinic recognition sites in human brain: characterization of agonist binding. <i>Neuroscience Letters</i> , <b>1987</b> , 83, 298-302	3.3	23
152	Tolerance, physical dependence and changes in muscarinic receptor binding sites after chronic ethanol treatment in the rat. <i>Life Sciences</i> , <b>1982</b> , 31, 277-87	6.8	23
151	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , <b>2021</b> ,	6.5	23

150	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1152-1163	8.8	23
149	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 348-356	8.8	23
148	Effect of nicotine on the release of acetylcholine and amino acids in the brain. <i>Progress in Brain Research</i> , <b>1989</b> , 79, 149-55	2.9	22
147	The regulation in vitro of placental release of human chorionic gonadotropin, placental lactogen, and prolactin: effects of an adrenergic beta-receptor agonist and antagonist. <i>American Journal of Obstetrics and Gynecology</i> , <b>1982</b> , 143, 444-50	6.4	22
146	Promising two-photon probes for in vivo detection of $\beta$ amyloid deposits. <i>Chemical Communications</i> , <b>2014</b> , 50, 11694-7	5.8	21
145	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 419-430	1.2	21
144	Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. <i>Neurochemistry International</i> , <b>2007</b> , 50, 800-6	4.4	21
143	Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation. <i>Journal of Neuroscience Research</i> , <b>2003</b> , 71, 397-406	4.4	21
142	Selective decreases of nicotinic acetylcholine receptors in PC12 cells exposed to fluoride. <i>Toxicology</i> , <b>2003</b> , 183, 235-42	4.4	21
141	Toward an early diagnosis and treatment of Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2003</b> , 15, 223-37	3.4	20
140	Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. <i>Journal of Neuroscience Research</i> , <b>2005</b> , 82, 531-41	4.4	20
139	Synthesis and characterization of binding of 5-[ <sup>76</sup> Br]bromo-3-[[2(S)-azetidiny]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. <i>Journal of Neurochemistry</i> , <b>1999</b> , 73, 1264-72	6	20
138	Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APP <sup>sw</sup> and PS1 double transgenic mice. <i>Neuroscience Letters</i> , <b>2002</b> , 328, 269-72	3.3	19
137	Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile. <i>Journal of Neural Transmission</i> , <b>1987</b> , 69, 19-32	4.3	19
136	Regional biosynthesis of acetylcholine in brain following forced oral chronic barbitone treatment to rat. <i>Journal of Neurochemistry</i> , <b>1979</b> , 32, 371-8	6	19
135	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 388-399	1.2	19
134	Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. <i>European Journal of Pharmacology</i> , <b>1990</b> , 186, 301-5	5.3	18
133	Effect of oxotremorine on the apparent regional turnover of acetylcholine in mouse brain. <i>Journal of Neurochemistry</i> , <b>1978</b> , 30, 383-9	6	18

132	Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 39, 423-40	4.3	17
131	Effect of oxotremorine on endogenous acetylcholine and on uptake and biotransformation of radioactive choline in discrete regions of mouse brain in vivo. <i>Biochemical Pharmacology</i> , <b>1976</b> , 25, 135-40	6	17
130	Regional high affinity synaptosomal transport of choline in mouse brain--influence of oxotremorine treatment. <i>Life Sciences</i> , <b>1978</b> , 23, 937-44	6.8	17
129	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 94, e2026-e2036	6.5	17
128	Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1031-1042	1.2	16
127	Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. <i>ACS Chemical Neuroscience</i> , <b>2020</b> , 11, 900-908	5.7	16
126	Characterization of the brain $\beta$ amyloid isoform pattern at different ages of Tg2576 mice. <i>Neurodegenerative Diseases</i> , <b>2011</b> , 8, 352-63	2.3	16
125	In vitro evaluation of $^{11}\text{C}$ -labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidide as nicotinic receptor ligands for positron emission tomography studies. <i>Journal of Neurochemistry</i> , <b>1998</b> , 71, 1750-60	6	16
124	Acetylcholine synthesizing activity and nicotinic binding sites in rat hind limb muscles during reinnervation. <i>Acta Physiologica Scandinavica</i> , <b>1982</b> , 116, 429-35		16
123	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1457-1468	1.2	16
122	Correlation of oxidative stress and the loss of the nicotinic receptor alpha 4 subunit in the temporal cortex of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2003</b> , 338, 13-6	3.3	15
121	Neuroprotection in Alzheimer's disease - new strategies for treatment. <i>Neurotoxicity Research</i> , <b>2000</b> , 2, 157-65	4.3	15
120	Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidide (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. <i>Neurochemistry International</i> , <b>1998</b> , 32, 435-41	4.4	14
119	Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. <i>Neuroscience Letters</i> , <b>2003</b> , 340, 148-52	3.3	14
118	Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment. <i>Drug and Alcohol Dependence</i> , <b>1981</b> , 7, 51-61	4.9	14
117	Decreased brain weights in rats after long-term barbital treatments. <i>Life Sciences</i> , <b>1978</b> , 23, 1583-90	6.8	14
116	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1750, 231-251	1.4	14
115	Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192-IgG saporin lesions of the nucleus basalis magnocellularis. <i>International Journal of Developmental Neuroscience</i> , <b>1998</b> , 16, 661-8	2.7	13

114	Early changes in Abeta levels in the brain of APPswe transgenic mice—implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels. <i>Molecular and Cellular Neurosciences</i> , <b>2005</b> , 30, 218-27	4.8	13
113	In vitro binding of 3H-acetylcholine to nicotinic receptors in rodent and human brain. <i>Journal of Neural Transmission</i> , <b>1987</b> , 69, 3-18	4.3	13
112	Development of [C]/[H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand. <i>Nuclear Medicine and Biology</i> , <b>2017</b> , 46, 50-53	2.1	12
111	Pharmacodynamic effects of nicotine and acetylcholine biosynthesis in mouse brain. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1983</b> , 52, 341-7		12
110	Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. <i>Progress in Brain Research</i> , <b>2004</b> , 145, 301-10	2.9	12
109	Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. <i>Neuropharmacology</i> , <b>2004</b> , 47, 558-71	5.5	12
108	Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. <i>Neurochemistry International</i> , <b>2004</b> , 45, 1049-55	4.4	12
107	Differential co-expression of nicotinic acetylcholine receptor alpha 4 and beta 2 subunit genes in various regions of rat brain. <i>NeuroReport</i> , <b>1996</b> , 7, 1645-9	1.7	12
106	Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	12
105	Molecular imaging of neuroinflammation in Alzheimer's disease. <i>Clinical and Translational Imaging</i> , <b>2015</b> , 3, 437-447	2	11
104	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 652-663	1.2	11
103	Influence of lipid peroxidation on the nicotinic acetylcholine receptors in PC12 cells. <i>Neuroscience Letters</i> , <b>2000</b> , 286, 163-6	3.3	11
102	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1081-1103	1.2	10
101	CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 239	6.1	10
100	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 661-7	4.3	10
99	Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1996</b> , 7, 111-7	2.6	10
98	Different interactions of steric isomers of hexobarbital to muscarinic agonist and antagonist binding sites in brain. <i>Brain Research</i> , <b>1984</b> , 310, 189-92	3.7	10
97	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2070-2085	8.8	10



96	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 80, 1723-1737	4.3	10
95	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1492-506	8.8	9
94	Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells. <i>Journal of Neuroscience Research</i> , <b>2007</b> , 85, 504-14	4.4	9
93	Rats exhibiting acute behavioural tolerance to nicotine have more [ <sup>125</sup> I]alpha-bungarotoxin binding sites in brain than rats not exhibiting tolerance. <i>Behavioural Brain Research</i> , <b>2000</b> , 113, 105-15	3.4	9
92	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
91	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2110-2120	8.8	9
90	[F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	8
89	Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2006</b> , 18, S3-S16	3.4	8
88	Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinesterase. <i>International Journal of Developmental Neuroscience</i> , <b>2004</b> , 22, 545-9	2.7	8
87	[ <sup>3</sup> H]muscimol and [ <sup>3</sup> H]quinuclidinyl benzilate binding in rat cortex in the abstinence after long-term barbital treatment. <i>Acta Physiologica Scandinavica</i> , <b>1986</b> , 126, 153-6		8
86	Diurnal fluctuation in striatal choline acetyltransferase activity and strain difference in brain protein content of the rat. <i>Acta Physiologica Scandinavica</i> , <b>1980</b> , 108, 385-8		8
85	Effect of denervation on acetylcholine synthesizing activity and nicotine-like binding sites in rat hind limb muscles. <i>Acta Physiologica Scandinavica</i> , <b>1982</b> , 114, 345-50		8
84	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , <b>2021</b> , 298, 517-530	20.5	8
83	Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid $\beta$ Fibril. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1783-1790	5.7	7
82	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- $\beta$ positivity. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	7
81	Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. <i>International Journal of Developmental Neuroscience</i> , <b>2006</b> , 24, 269-73	2.7	7
80	Effect of acute and subchronic nicotine treatment on cortical efflux of [ <sup>3</sup> H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. <i>British Journal of Pharmacology</i> , <b>1991</b> , 104, 15-20	8.6	7
79	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 691-704	4.3	7

78	Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 1093-1102	8.8	7
77	Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy. <i>ACS Chemical Neuroscience</i> , <b>2021</b> , 12, 2437-2447	5.7	7
76	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A $\beta$ species. <i>NeuroImage: Clinical</i> , <b>2018</b> , 20, 603-610	5.3	7
75	Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	7
74	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 327-332	5.2	6
73	Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the $\alpha$ 7 nicotinic acetylcholine receptor. <i>Physical Chemistry Chemical Physics</i> , <b>2016</b> , 18, 28003-28009	2.6	6
72	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , <b>2019</b> , 266, 2535-2545	5.5	6
71	Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies. <i>ACS Chemical Neuroscience</i> , <b>2017</b> , 8, 2655-2666	5.7	6
70	The future: new methods of imaging exploration in Alzheimer's disease. <i>Frontiers of Neurology and Neuroscience</i> , <b>2009</b> , 24, 47-53	1.1	6
69	Use of carbon-11 nicotine in PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1997</b> , 24, 825-6		6
68	Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells. <i>Cellular and Molecular Neurobiology</i> , <b>2006</b> , 26, 225-35	4.6	6
67	Temporal studies of the inhibition of voluntary ethanol intake in the rat induced by intermittent ethanol treatment and some long term neurochemical consequences. <i>Drug and Alcohol Dependence</i> , <b>1991</b> , 28, 129-44	4.9	6
66	Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex. <i>Journal of Neural Transmission</i> , <b>1988</b> , 72, 11-8	4.3	6
65	Relation between voluntary ethanol intake in rats and changes in striatal muscarinic binding sites seen after induction of stable ethanol intake by an intermittent ethanol treatment. <i>Brain Research</i> , <b>1988</b> , 474, 189-91	3.7	6
64	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , <b>2020</b> , 10, 555-565	2.7	6
63	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa192	4.5	5
62	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: A $\beta$ Parc and PSEN1DE9. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	5
61	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 45	9	5

60	Molecular imaging in sporadic Alzheimer's disease populations and those genetically at risk. <i>Neurodegenerative Diseases</i> , <b>2014</b> , 13, 160-2	2.3	5
59	Effect of oxotremorine and sodium pentobarbitone on the pharmacokinetics of intravenous tracer doses or radioactive choline. <i>Journal of Pharmacy and Pharmacology</i> , <b>1977</b> , 29, 96-8	4.8	5
58	Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1997</b> , 8, 259-66	2.6	5
57	Apolipoprotein E varepsilon4 allele has an impact on vascular reactivity in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , <b>2000</b> , 31, 221-231	4	5
56	Clinical impact of F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 612-622	8.8	5
55	Homomeric and Heteromeric A $\beta$ species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 176	6.1	4
54	The use of amyloid imaging in clinical praxis: a critical review. <i>Clinical and Translational Imaging</i> , <b>2015</b> , 3, 7-11	2	4
53	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2004</b> , 31, 1540-3	8.8	4
52	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease	153-164	4
51	Influence of age on effects induced by intermittent ethanol treatment on the ethanol drinking pattern and related neurochemical changes in the rat. <i>Drug and Alcohol Dependence</i> , <b>1988</b> , 22, 117-28	4.9	4
50	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2086-2096	8.8	4
49	Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the $\alpha 7$ nicotinic acetylcholine receptor. <i>RSC Advances</i> , <b>2017</b> , 7, 19787-19793	3.7	3
48	Modulation of choline transport and acetylcholine synthesis in synaptosomes from different brain regions. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1985</b> , 56, 193-8		3
47	Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2002</b> , 13, 199-204	2.6	3
46	Future prospects of research on central cholinergic mechanisms. <i>Progress in Brain Research</i> , <b>1990</b> , 84, 415-8	2.9	3
45	Long-term effects on biotransformation of labelled choline in different parts of the rat brain induced by single choline injections. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1988</b> , 62, 69-73		3
44	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2183-2199	8.8	3
43	Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils. <i>ACS Chemical Neuroscience</i> , <b>2021</b> , 12, 3487-3496	5.7	3

42	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101681	5.3	2
41	[IC-P-178]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING <b>2017</b> , 13, P133-P133		2
40	Atropine modulates changes in striatal muscarinic receptor binding sites in barbitol abstinence in the rat. <i>Acta Physiologica Scandinavica</i> , <b>1982</b> , 115, 369-71		2
39	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease.. <i>Journal of Neurochemistry</i> , <b>2021</b> ,	6	2
38	PET Tracers for Beta-Amyloid and Other Proteinopathies <b>2014</b> , 199-212		2
37	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. <i>Neurobiology of Aging</i> , <b>2019</b> , 82, 40-47	5.6	1
36	O4-02-05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENIC MICE: A MULTI-TRACER MICROPET STUDY <b>2014</b> , 10, P253-P253		1
35	[P2B66]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING <b>2017</b> , 13, P765-P765		1
34	Pharmacological modulation of transmitter activity in Alzheimer brains--an experimental model. <i>Acta Neurologica Scandinavica</i> , <b>1990</b> , 129, 17-20	3.8	1
33	Abeta(25-35) attenuated SREBP level in nuclear extracts of serum-deprived human neuroblastoma cells. <i>Neurochemical Research</i> , <b>2009</b> , 34, 845-50	4.6	1
32	Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , <b>1996</b> , 22, 223-32	4	1
31	New approaches to clinical and postmortem investigations of cholinergic mechanisms. <i>Progress in Brain Research</i> , <b>1990</b> , 84, 313-20	2.9	1
30	Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography <b>2006</b> , 181-190		1
29	Different patterns of PIB uptake in AD patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S666-S666	7.3	1
28	Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , <b>2021</b> , 96, 238	6.5	1
27	Subcortical and Cortical Regions of Amyloid-Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 81, 1613-1624	4.3	0
26	In silico studies of ASEM analogues targeting $\alpha 7$ -nAChR and experimental verification. <i>RSC Advances</i> , <b>2021</b> , 11, 3942-3951	3.7	0
25	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 84, 103-117	4.3	0

24	IC-P-126: Divergent pattern of changes in astrogliosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease <b>2015</b> , 11, P86-P86	
23	P4-254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol <b>2015</b> , 11, P878-P878	
22	O4-07-05: 18F-(S).THK5117 as a PET tracer for tau pathology in Alzheimer's disease and non-alzheimer's disease dementia <b>2015</b> , 11, P285-P285	
21	O1-02-03: Divergent pattern of changes in astrogliosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease <b>2015</b> , 11, P127-P127	
20	[P4074]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES <b>2017</b> , 13, P1390-P1390	
19	[IC-P-016]: INVESTIGATING THE CLINICAL IMPACT OF [18F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS <b>2017</b> , 13, P19-P20	
18	[IC-P-189]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES <b>2017</b> , 13, P139-P140	
17	[P1B57]: INVESTIGATING THE CLINICAL IMPACT OF [18F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS <b>2017</b> , 13, P394-P395	
16	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset <b>2015</b> , 11, P140-P142	
15	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. <i>Neurocase</i> , <b>2015</b> , 21, 738-47	0.8
14	Imaging and behavior in Parkinson's disease: functional imaging	89-96
13	Interview: Imaging in Alzheimer's Disease. <i>Imaging in Medicine</i> , <b>2011</b> , 3, 389-392	1
12	Preface. <i>Behavioural Brain Research</i> , <b>2000</b> , 113, 1	3-4
11	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant Aβ <sub>PP2C</sub> Alzheimer's disease.. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 5471	15.1
10	Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation. <i>Advances in Behavioral Biology</i> , <b>2002</b> , 183-186	
9	Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S415-S415	7.3
8	Nicotinic Receptors as a new Target for Treatment of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , <b>1998</b> , 463-468	
7	P3-262: TAU PET Imaging in Non-Alzheimer's Disease Dementia: a Multimodal Paradigm <b>2016</b> , 12, P932-P933	

- 6 P1-306: Association Between in Vivo TAU Deposition Measured Using [18F]THK5317 Pet and Cognitive Functions in Alzheimer's Disease **2016**, 12, P539-P540
- 5 IC-P-170: In Vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic AD Brain in Comparison With Sporadic AD Brain Using 3H-PIB, 3H-THK5117 and 3H-Deprenyl **2016**, 12, P124-P124
- 4 IC-P-189: TAU PET Imaging in Non-Alzheimer's Disease Dementia: A Multimodal Paradigm **2016**, 12, P137-P137
- 3 O4-07-03: Longitudinal Changes in Regional Tau Deposition in Alzheimer's Disease and other Tauopathies Measured by [18F]-TKH5317 Pet in a Multi-Tracer Design **2016**, 12, P348-P349
- 2 P1-105: In vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic Alzheimer's Disease Brain in Comparison With Sporadic Alzheimer's Disease Brain Using 3H-PIB, 3H-THK5117 and 3H-DEPRENYL **2016**, 12, P442-P442
- 1 P4-349: EARLY-PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease **2016**, 12, P1171-P1171